Manufacturers Life Insurance Company, The Relmada Therapeutics, Inc. Transaction History

Manufacturers Life Insurance Company, The

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$2.22 - $3.54 $10,420 - $16,616	-4,694 Reduced 18.75%	20,343 $50,000
Q4 2022 Aug 11, 2023	SELL	$2.17 - $35.84 $11,702 - $193,285	-5,393 Reduced 17.72%	25,037 $87,000
Q4 2022 Feb 13, 2023	SELL	$2.17 - $35.84 $11,702 - $193,285	-5,393 Reduced 17.72%	25,037 $87,000
Q3 2022 Aug 11, 2023	SELL	$18.3 - $37.02 $5,032 - $10,180	-275 Reduced 0.9%	30,430 $1.13 Million
Q3 2022 Nov 03, 2022	SELL	$18.3 - $37.02 $5,032 - $10,180	-275 Reduced 0.9%	30,430 $1.11 Million
Q2 2022 Aug 11, 2023	BUY	$16.5 - $30.34 $272,233 - $500,579	16,499 Added 116.14%	30,705 $583,000
Q2 2022 Aug 15, 2022	BUY	$16.5 - $30.34 $272,233 - $500,579	16,499 Added 116.14%	30,705 $590,000
Q1 2022 Aug 11, 2023	SELL	$16.72 - $26.99 $181,094 - $292,328	-10,831 Reduced 43.26%	14,206 $383,000
Q1 2022 May 20, 2022	BUY	$16.72 - $26.99 $237,524 - $383,419	14,206 New	14,206 $379,000
Q4 2021 Feb 16, 2022	SELL	$16.93 - $26.82 $142,330 - $225,475	-8,407 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$21.86 - $34.77 $9,028 - $14,360	-413 Reduced 4.68%	8,407 $220,000
Q2 2021 Aug 12, 2021	BUY	$29.55 - $39.15 $15,159 - $20,083	513 Added 6.18%	8,820 $282,000
Q1 2021 May 03, 2021	SELL	$31.52 - $39.28 $14,908 - $18,579	-473 Reduced 5.39%	8,307 $292,000
Q4 2020 Feb 12, 2021	BUY	$29.88 - $39.8 $19,661 - $26,188	658 Added 8.1%	8,780 $282,000
Q2 2020 Aug 10, 2020	BUY	$31.59 - $49.98 $256,573 - $405,937	8,122 New	8,122 $350,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.